GRI Bio, Inc. (GRI) earnings
GRI earnings moved a median of -2.31% by the close. Quarterly and annual GRI reports and results, each read against the price at its own news timestamp. Back to the GRI overview →
17 measured GRI earnings events.
Where these GRI earnings landedvs 16 measured GRI earnings reactions
| Middle 50% of GRI earnings reactions | -4.23% to +3.87% |
|---|---|
| Median reaction (to close) | -2.31% |
| Measured reactions | 16 |
Point-in-time · zero look-ahead
Half of the 16 GRI earnings events with a measured close landed between -4.23% and +3.87%; 38% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q GRI Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | — | |
| Form 10-Q GRI Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.55% | -8.24% | |
| GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline | Press release | -0.44% | -3.59% | |
| Form 10-Q GRI Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.44% | -3.59% | |
| Form 10-K GRI Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.37% | -3.26% | |
| Form 10-Q GRI Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.88% | +5.63% | |
| Form 10-Q GRI Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.15% | +10.77% | |
| Form 10-Q GRI Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -1.36% | |
| GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 | Press release | +0.00% | -1.36% | |
| Form 10-K GRI Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -6.18% | |
| Form 10-Q GRI Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | +8.22% | +5.77% | |
| GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis | Press release | +8.22% | +5.77% | |
| Form 10-Q GRI BIO, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.15% | -9.00% | |
| GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.15% | -9.00% | |
| GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.27% | +3.29% | |
| Form 10-Q GRI BIO, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.27% | +3.29% | |
| Form 10-K GRI BIO, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -3.36% |
Keep exploring
More GRI: analyst actions → · SEC filings → · GRI overview →